# Daewoong Pharmaceutical plans $74.6M botulinum toxin plant in Hwaseong

Daewoong Pharmaceutical plans to invest 100 billion won ($74.6 million) to build a third botulinum toxin production facility in Hwaseong, Gyeonggi Province, South Korea. Construction is expected to start in H1 2023 and be completed by 2024, adding capacity for up to 18 million vials per year.

- Type: New facility
- Announced: 2023-05-03
- Where: Hwaseong, Gyeonggi Province, South Korea
- Value: $74.6M
- Starts operating: 2024
- Status: announced
- Capacity: 18 million vials per year
- Products: botulinum toxin product Nabota

## Companies

- [Daewoong Pharmaceutical](https://endata.com/companies/70094.md)

## Sources

- [fiercepharma.com](https://www.fiercepharma.com/manufacturing/daewoong-inject-746m-plumping-its-botox-production), 2023-05-03: "With the construction of the third plant, we will expand the Nabota business in earnest, including entering the therapeutic indication market and the Chinese market, and developing next-generation formulations."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.